AU Patent

AU2010202330B2 — N4-phenyl-quinazoline-4 -amine derivatives and related compounds as ERBB type 1 receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases

Assigned to Array Biopharma Inc · Expires 2012-07-19 · 14y expired

What this patent protects

This invention provides compounds of Formula (I), wherein B, G, A, E, R', R2, R3, m and n are as defined herein, which are useful as type I receptor tyrosine kinase inhibitors, and methods of use thereof in the treatment of hyperproliferative disorders in mammals.

USPTO Abstract

This invention provides compounds of Formula (I), wherein B, G, A, E, R', R2, R3, m and n are as defined herein, which are useful as type I receptor tyrosine kinase inhibitors, and methods of use thereof in the treatment of hyperproliferative disorders in mammals.

Drugs covered by this patent

Patent Metadata

Patent number
AU2010202330B2
Jurisdiction
AU
Classification
—
Expires
2012-07-19
Drug substance claim
No
Drug product claim
No
Assignee
Array Biopharma Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.